Onyx Pharma Inc (ONXX)
Price: $31.75
Industry: Drugs Chaikin Power Gauge Report | Generated: Thu Sep 22 16:08 EDT 2011 ONXX Onyx Pharma Inc
$31.75
Power Gauge Rating
ONXX - Very Bearish TM
The Chaikin Power Gauge Rating for ONXX is very bearish due to very poor financial metrics, weak earnings performance and negative expert opinions. The rating also reflects bullish price/volume activity.
Financial Metrics
ONXX's financial metrics are very poor due to a low return on equity. Earnings Performance
ONXX's earnings performance is weak as a result of worse than expected earnings in recent quarters.
Price/Volume Activity
Expert Opinions
News Sentiment Rating
Neutral ONXX Onyx Pharma ..
September 09, 2011
TM
Chaikin Sentiment Gauge for ONXX is neutral. Stories concerning ONXX have a balanced or neutral sentiment.
News Sentiment :Neutral
Power Trend - 5 Year Chart
The Power Gauge distills a 20 factor model into a concise picture of a stock's potential.
I want to receive special offers about trading stocks with your brokerage partner, optionsXpress. Click here
High Potential
Neutral
Low Potential
www.chaikinpowertools.com
Financials & Earnings
Financial Metrics
Financial Metrics Rating
Very Bearish
LT Debt/Equity Ratio
ONXX's financial metrics are very poor. The company yields a relatively low return on shareholder's equity and is carrying too much long term debt.
Price to Book Value
The rank is based on a high long term debt to equity ratio, high price to book value ratio and low return on equity.
Return on Equity
Price to Sales Ratio
Business Value
Assets and Liabilities
Valuation
Ratio
TTM
Current Ratio LT Debt/Equity
Returns
Ratio
TTM
Ratio
12.30
Price/Book
3.24
Return on Invest
-3.4%
0.22
Price/Sales
6.22
Return on Equity
-4.2%
Earnings Performance
TTM
Earnings Performance Rating
Bearish
Earnings Growth
ONXX's earnings performance has been weak. The company has not met analysts' earnings estimates and has a history of weak earnings growth.
Earnings Surprise
The rank is based on worse than expected earnings in recent quarters and consistent earnings over the past 5 years.
Earnings Trend
Projected P/E Ratio
Earnings Consistency
5 Year Revenue and Earnings Growth
Revenue(M) Rev % Growth EPS EPS % Growth
EPS Estimates
12/06
12/07
12/08
12/09
12/10
0.25
-
194.34
251.39
324.52
-75.00%
-
-
29.35%
29.09%
$-2.20
$-0.67
$0.03
$0.27
$-1.35
16.67%
69.55%
104.48%
800.00%
-600.00%
EPS Surprise
Factor
Actual EPS Prev
EST EPS Current
Change
$0.66
$-0.32
-0.98
Quarterly EPS Yearly EPS Factor
$-1.35
$-1.76
-0.41
Actual EPS Growth
Est EPS Growth
Change
-5.52%
43.00%
+48.52
3-5 year EPS
EPS Quarterly Results Estimate
Actual
Difference
% Difference
FY
Latest Qtr
$-0.34
$-0.43
$-0.09
-26.47
12/09
1 Qtr Ago
$-0.29
$-0.31
$-0.02
-6.90
12/10
2 Qtr Ago
$-0.11
$-0.36
$-0.25
-227.27
12/11
$-0.78
3 Qtr Ago
$-0.04
$0.66
$0.70
1750.00
Fiscal Year End Month is December.
I want to receive special offers about trading stocks with your brokerage partner, optionsXpress. Click here
Qtr 1
Qtr 2
Qtr 3
Qtr 4
$0.07
$0.16
$0.14
$-0.09
$0.28
$-0.19
$-1.55
$0.66
$-0.27
$-1.35
$-0.86
-
-
-
www.chaikinpowertools.com
Total
Price Trend & Expert Opinions Price/Volume Activity
Price/Volume Activity Rating
Bullish
Relative Strength vs Market
Chaikin Money Flow
Price and volume activity for ONXX is bullish. ONXX has outperformed the S&P 500 over 26 weeks and is experiencing sustained buying.
Price Trend
The rank for ONXX is based on its price strength versus the market, positive Chaikin money flow, a positive Chaikin price trend and a decreasing volume trend.
Price Trend ROC
Volume Trend
Relative Strength vs S&P500 Index
Chaikin Money Flow
Chart shows whether ONXX is performing better or worse than the market.
Chaikin Money Flow analyzes supply and demand for a company's stock.
Price Activity
Price Activity
Factor
Value
Factor
52 Week High
45.37
52 Week Low
25.53
% Change YTD Rel S&P 500
-8.33%
Expert Opinions
Volume Activity Value
Factor
% Change Price - 4 Weeks
0.00%
Average Volume 20 Days
694,041
% Change Price - 24 Weeks
-6.59%
Average Volume 90 Days
863,598
% Change Price - 4 Wks Rel to S&P
0.93%
% Change Price - 24 Wks Rel to S&P
6.92%
Value
Chaikin Money Flow Persistency
58%
Expert Opinions
Bearish
Earnings Estimate Revisions
Expert opinions about ONXX are negative. Analysts are lowering their EPS estimates for ONXX and short interest in ONXX is high.
Short Interest
Insider Activity
The rank for ONXX is based on analysts revising earnings estimates downward, a high short interest ratio, insiders purchasing stock, optimistic analyst opinions and price strength of the stock versus the Drugs industry group.
Analyst Opinions
Relative Strength vs Industry
Earnings Estimate Revisions Current Current Qtr Next Qtr
-0.32 -0.56 Current
Current FY
-1.76
Analyst Recommendations
7 Days Ago % Change -0.32 -0.56
0.00% 0.00%
30 Days Ago % Change -1.94
0.18
Factor Mean this Week Mean Last Week Change Mean 5 Weeks Ago
I want to receive special offers about trading stocks with your brokerage partner, optionsXpress. Click here
EPS Estimates Revision Summary Value
Last Week Down
Up
Down
Curr Qtr
0
0
0
0
Curr Yr
0
0
1
0
Next Qtr
0
0
0
0
Next Yr
0
0
0
0
Buy Buy -0.06
Last 4 Weeks
Up
Buy
www.chaikinpowertools.com
The Company & Its Competitors
News Headlines for ONXX
ONXX's Competitors in Drugs Company
Power Gauge
Historic EPS growth
Projected EPS growth
Profit Margin
PEG
PE
Revenue(M)
-5.52%
43.00%
-24.19%
-
-
325
9.84%
-2.00%
26.36%
-4.20
6.98
4,420
WCRX
45.93%
10.78%
4.28%
0.38
4.20
2,974
ENDP
15.95%
13.22%
12.13%
0.46
7.08
1,716
SHPGY
17.38%
15.68%
17.66%
1.13
19.71
3,471
ELN
19.58%
-
-6.04%
-
-
1,170
VRX
7.07%
16.53%
-9.29%
0.86
27.07
1,181
ONXX FRX
Pfizer files for US approval of kidney cancer drug - Jun 28, 2011 Onyx Pharmaceuticals Receives Fast Track Designation for Carfilzomib; Company Initiates Rolling NDA Submission for Accelerated Approval - Jan 31, 2011 Apricus, FDA agree on liver cancer drug study Nov 22, 2010 SBIO JAK2 Inhibitor 10 18 - Oct 18, 2010 Onyx Pharmaceuticals Provides Status Update on Carfilzomib - Oct 7, 2010
Company Details
Company Profile
ONYX PHARMA INC 249 E. GRAND AVE. SOUTH SAN FRANCISCO, CA 94080 USA Phone: 650-266-0000 Fax: 650-266-0100 Website: http://http://www.onyxpharm.com/ Full Time Employees: 299 Sector: Medical
Onyx Pharmaceuticals, Inc is developing innovative products for the treatment of cancer.
Power Gauge Ratings are created using a relative ranking system that assigns a rank of 0 to 100 (100 being the highest) to each stock in the universe. Rank is calculated by evaluating each of the stocks factors and combining them into a single number using a weighting formula. A stock's rank ranges from 100-0, where 100 is the strongest, and a rank of 95 indicates the stock is better than 95% of the stocks in the universe. Chaikin Stock Research(CSR) is not registered as a securities broker dealer or investment advisor with either the U.S. Securities and Exchange Commission or with any state securities regulatory authority. CSR is not responsible for trades executed by users of this research report, our web site or mobile app based on the information included herein. The information presented in this report does not represent a recommendation to buy or sell stocks or any financial instrument nor is it intended as an endorsement of any security or investment. The information in this report is generic by nature and is not personalized to the specific financial situation of any individual. The user bears complete responsibility for their own investment research and should seek the advice of a qualified investment professional before making any investment decisions. Copyright (c) 1978-(Present) by ZACKS Investment Research, Inc ("ZACKS"). The information, data, analyses and opinions contained herein (1) includes the confidential and proprietary information of ZACKS, (2) may not be copied or redistributed, for any purpose, (3) does not constitute investment advice offered by ZACKS, (4) are provided solely for informational purposes, and (5) are not warranted or represented to be correct, complete, accurate or timely. ZACKS shall not be responsible for investment decisions, damages or other losses resulting from, or related to, use of this information, data, analyses or opinions. Past performance is no guarantee of future performance. ZACKS is not affiliated with Chaikin Power Tools. This report from Chaikin Power Tools is for informational purposes only and is not a recommendation to buy or sell securities.
LM 2.3 DS 3.0 LS 2.1
Data Provided by ZACKS Investment Research, Inc., www.zacks.com
Special offers to trade stocks from optionsXpress: www.chaikinpowertools.com